Advancing CNS Therapeutics: Enhancing Neurological Disorders with Nanoparticle-Based Gene and Enzyme Replacement Therapies

被引:0
作者
Liu, Shuhan [1 ,2 ,3 ]
Li, Haisong [4 ]
Xi, Shiwen [1 ,2 ]
Zhang, Yuning [1 ,2 ]
Sun, Tianmeng [1 ,2 ,5 ,6 ]
机构
[1] Jilin Univ, Minist Educ, Hosp 1, Inst Immunol,Key Lab Organ Regenerat & Transplanta, Changchun, Jilin, Peoples R China
[2] Natl Local Joint Engn Lab Anim Models Human Dis, Changchun, Peoples R China
[3] Jilin Univ, Hosp 1, Canc Ctr, Changchun, Jilin, Peoples R China
[4] Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China
[5] Jilin Univ, Int Ctr Future Sci, Changchun, Peoples R China
[6] Jilin Univ, State Key Lab Supramol Struct & Mat, Changchun, Peoples R China
来源
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2025年 / 20卷
关键词
central nervous system; nanoparticle; gene therapy; enzyme replacement therapy; lysosomal storage disorders; neurological disorders; BLOOD-BRAIN-BARRIER; SOLID LIPID NANOPARTICLES; DELIVERY-SYSTEM; MESSENGER-RNA; MUCOPOLYSACCHARIDOSIS-II; SILICA NANOPARTICLES; NANOMEDICINE; CELLS; MECHANISMS; DISEASE;
D O I
10.2147/IJN.S457393
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Given the complexity of the central nervous system (CNS) and the diversity of neurological conditions, the increasing prevalence of neurological disorders poses a significant challenge to modern medicine. These disorders, ranging from neurodegenerative diseases to psychiatric conditions, not only impact individuals but also place a substantial burden on healthcare systems and society. A major obstacle in treating these conditions is the blood-brain barrier (BBB), which restricts the passage of therapeutic agents to the brain. Nanotechnology, particularly the use of nanoparticles (NPs), offers a promising solution to this challenge. NPs possess unique properties such as small size, large surface area, and modifiable surface characteristics, enabling them to cross the BBB and deliver drugs directly to the affected brain regions. This review focuses on the application of NPs in gene therapy and enzyme replacement therapy (ERT) for neurological disorders. Gene therapy involves altering or manipulating gene expression and can be enhanced by NPs designed to carry various genetic materials. Similarly, NPs can improve the efficacy of ERT for lysosomal storage disorders (LSDs) by facilitating enzyme delivery to the brain, overcoming issues like immunogenicity and instability. Taken together, this review explores the potential of NPs in revolutionizing treatment options for neurological disorders, highlighting their advantages and the future directions in this rapidly evolving field.
引用
收藏
页码:1443 / 1490
页数:48
相关论文
共 179 条
[1]  
Teleanu RI, Preda MD, Niculescu AG., Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier, Pharmaceutics, 14, 5, (2022)
[2]  
Amin ND, Pasca SP., Building Models of Brain Disorders with Three-Dimensional Organoids, Neuron, 100, 2, pp. 389-405, (2018)
[3]  
Andjelkovic AV, Stamatovic SM, Phillips CM, Martinez-Revollar G, Keep RF., Modeling blood-brain barrier pathology in cerebrovascular disease in vitro: current and future paradigms, Fluids Barriers CNS, 17, 1, (2020)
[4]  
Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV., Blood-Brain Barrier: from Physiology to Disease and Back, Physiol Rev, 99, 1, pp. 21-78, (2019)
[5]  
Lingineni K, Belekar V, Tangadpalliwar SR, Garg P., The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood– brain barrier (BBB) permeability, Mol Diver, 21, 2, pp. 355-365, (2017)
[6]  
Naqvi S, Panghal A, Flora SJS., Nanotechnology: a Promising Approach for Delivery of Neuroprotective Drugs, Front Neurosci, 14, (2020)
[7]  
Hersh AM, Alomari S, Tyler BM., Crossing the Blood-Brain Barrier: advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology, Int J Mol Sci, 23, 8, (2022)
[8]  
Teixeira MI, Lopes CM, Amaral MH, Costa PC., Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases, Colloids Surf B, 221, (2023)
[9]  
Cullis PR, Hope MJ., Lipid Nanoparticle Systems for Enabling Gene Therapies, Mol Ther, 25, 7, pp. 1467-1475, (2017)
[10]  
Sato Y, Okuyama T., Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses, Int J Mol Sci, 21, 2, (2020)